Group items tagged

Diabetes Intensive Training is organized by Mayo clinic and would be held during Jul 10 - Sep 29, 2017. The target audience for this medical event basically for Endocrinology, Metabolism and Diabetes, The CME conference has been approved with maximum of 32.00 AMA PRA Category 1 Credit. he Diabetes Intensive Training online course is a comprehensive web based graduate credit level professional enhancement course geared toward practicing professionals. Diabetes Intensive Training is an online self-paced 12 week course through Blackboard Learn. The course is offered on a quarterly basis. The curriculum includes a pretest, 16 modules for study, a post-test requiring an 80% passing score for continuing education credit, and a required evaluation of the course at completion. Currently the curriculum is offered to physicians, physician assistants, advanced nurse practitioners, registered nurses and pharmacists with a current license without restrictions. Target audience: This course is designed for Primary care providers - Family Medicine and General Internal Medicine MDs, Pharmacists, Dietitians, NPs, RNs and APRNs. Learning objectives: Upon conclusion of this program, participants should be able to: * Integrate the principles of theory and research of nursing and medicine into comprehensive health care plan for patients with diabetes including prevention, promotion and treatment * Demonstrate knowledge of evidence based and clinical guidelines in treatment of diabetes inpatient and outpatient management. * Develop and acquire skills for self- directed lifelong learning and staying current in diabetes management (prevention, promotion and treatment).

Intensive blood pressure lowering may similarly decrease cardiovascular events in both patients with and patients without type 2 diabetes mellitus, according to a study published online Dec. 6 in Diabetes Care. Tom F. Brouwer, M.D., from the University of Amsterdam, and colleagues assessed the effect of both type 2 diabetes and baseline cardiovascular disease risk on the treatment effect of intensive blood pressure lowering based on data and pooled analysis from two randomized trials (ACCORD-BP [Action to Control Cardiovascular Risk in Diabetes Blood Pressure]and SPRINT [Systolic Blood Pressure Intervention Trial] studies; total of 14,094 patients). The researchers found that the mean baseline systolic blood pressure was 139.5 mm Hg for the cohort and just over one-third (33.6 percent) had type 2 diabetes. The hazard ratio for the primary composite end point of unstable angina, myocardial infarction, acute heart failure, stroke, and cardiovascular death was 0.82 (P = 0.0017). There was a nonsignificant interaction between intensive blood pressure lowering and type 2 diabetes (P = 0.13). While the 10-year cardiovascular risk was higher in patients with type 2 diabetes, there was no interaction between the risk and treatment effect (P = 0.84).

A new screening tool can adequately detect risk of diabetic retinopathy in adults with diabetes in low-income communities in Mexico, according to a study published in the October issue of Preventing Chronic Disease. Kenny Mendoza-Herrera, from the National Institute of Public Health in Mexico, and colleagues analyzed biochemical, clinical, anthropometric, and sociodemographic information from 1,000 adults with diabetes in low-income communities in Mexico in order to develop a screening tool based on a predictive model for early detection of diabetic retinopathy. Time since diabetes diagnosis, high blood glucose levels, systolic hypertension, and physical inactivity were risk factors included in the screening tool. The researchers found that the model had a mean area under the receiver operating characteristic curve (AUC ROC) of 0.78 in the validation data set. Using the optimized cut point that best represented the study population, the model had a sensitivity of 82.9 percent and a specificity of 61.9 percent. "We developed a low-cost and easy-to-apply screening tool to detect people at high risk of diabetic retinopathy in Mexico," the authors write. "Although classification performance of our tool was acceptable (AUC ROC > 0.75), error rates (precision) depend on false-negative and false-positive rates. Therefore, confirmatory assessment of all cases in mandatory."

For young patients with type 1 diabetes, insulin pump therapy is associated with lower risks of severe hypoglycemia and diabetic ketoacidosis and better glycemic control than insulin injection therapy, according to a study published online Oct. 10 in the Journal of the American Medical Association. Beate Karges, M.D., from RWTH Aachen University in Germany, and colleagues conducted a population-based cohort study in 446 diabetes centers. They identified patients with type 1 diabetes who were younger than 20 years and had diabetes duration of more than one year. The researchers found that 14,119 patients used pump therapy and 16,460 used insulin injections. A total of 9,814 patients using pump therapy were matched with 9,814 using injection therapy. Compared with injection therapy, pump therapy was correlated with lower rates of severe hypoglycemia (9.55 versus 13.97 per 100 patient-years) and diabetic ketoacidosis (3.64 versus 4.26 per 100 patient-years). Lower levels of glycated hemoglobin were seen with pump versus injection therapy (8.04 versus 8.22 percent). Compared with injection therapy, pump therapy was associated with lower total daily insulin doses (0.84 versus 0.98 U/kg). No significant difference in body mass index was seen between the treatment regimens

Management of type 2 diabetes should include shared decision making, and patients should be offered individualized diabetes self-management education and glycemic management plans, according to a summary of a clinical practice guideline published online Oct. 23 in the Annals of Internal Medicine. Paul R. Conlin, M.D., from the VA Boston Healthcare System in West Roxbury, Massachusetts, and colleagues convened a joint U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) Evidence-Based Practice Work Group to develop a guideline for management of type 2 diabetes mellitus. The authors provided updates on management within seven areas: patient-centered care and shared decision making, glycemic biomarkers, target ranges of hemoglobin A1c (HbA1c), individualized treatment plans, pharmacologic treatment in the outpatient setting, glucose targets for critically ill patients, and treatment for patients in the hospital. Patients should be offered individualized diabetes self-management education, as well as individualized glycemic management plans and target ranges for HbA1c. "In summary, the VA/DoD CPG [clinical practice guideline] attempts to convey to clinicians, policymakers, and patients the rationale for personalizing treatment on the basis of results from major trials, limitations of the HbA1c test, and evaluation of patient risk for adverse drug events. Conveying complex information in an understandable manner to individual patients and families through a formal process of shared decision making is thus foundational to setting and revising goals that are meaningful, safe, and achievable in everyday clinical practice," the authors write.

For patients with acute coronary syndromes (ACS), diabetes mellitus (DM), but not pre-DM, is associated with an increased risk of major adverse cardiac events (MACE), according to a study published online Oct. 18 in the Journal of the American College of Cardiology. Serdar Farhan, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the impact of pre-DM on coronary plaque characteristics and ischemic outcome in patients with ACS. Participants underwent quantitative coronary angiography, grayscale intravascular ultrasound (IVUS), and radiofrequency IVUS after successful percutaneous coronary intervention. Patients were categorized based on their glucometabolic status as normal glucose metabolism (NGM; 162 patients), pre-DM (202 patients), and DM (183 patients). The researchers found that there were no significant between-group differences with respect to IVUS findings indicative of vulnerable plaques. Compared to patients with pre-DM or NGM, patients with DM had a higher crude rate of MACE (25.9 versus 16.3 and 16.1 percent; P = 0.03 and 0.02, respectively). Using NGM as the reference group, DM, but not pre-DM, was correlated with increased risk of MACE in an adjusted model (hazard ratios, 2.2 [95 percent confidence interval, 1.25 to 3.86; P = 0.006] and 1.29 [95 percent confidence interval, 0.71 to 2.33; P = 0.41]).

The Global Diabetic Foot Ulcer Market was valued at $4.48 billion in 2018 and is anticipated to exhibit 11.34% CAGR from 2019 to 2026, reaching $ XX billion by 2026.

American Educational Institute (AEI) Medical-Dental-Legal Update is organized by American Educational Institute (AEI) and will be held during Oct 02, 2017 - Apr 27, 2018 at Grand Wailea Resort, Maui, Hawaii, United States of America. The target audience for this medical event is Dentists. This CME Conference has been approved for a maximum of 20 AMA PRA Category 1 Credits. Conference Description : You practice in a dynamic and challenging environment. While keeping clinically current is imperative, it isn't enough. You must also acquire the skills necessary to navigate a professional liability minefield, manage a more effective and efficient practice, and navigate a maze of healthcare laws and regulations. The 2017-18 Medical-Dental-Legal Update Update is designed to assist you in that endeavor. The course, offered weekly in 32 enviable destinations, is a unique, 20-hour survey of the intersection of medicine and law as well as selected clinical topics. Produced in state-of-the-art production studios with broadcast-grade, HD digital technology. This Conference offers vital instruction from national experts in the fields of law, medicine, dentistry, asset protection, revenue cycle management and practice management. And their presentations include discussions ranging from domestic violence, payment receipt optimization, medical malpractice, fraud and abuse, and optimizing retirement and benefit plan structures, to the oral-systemic connection, medical errors, Hepatitis B & C, neurology and cardiovascular fitness. The Update is presented in a structured classroom setting affording you the opportunity for dialogue with your medical, dental and legal colleagues, and through September 28, 2018, you will have over 900 opportu­nities to attend at your choice of 30 premier sun and ski resorts - virtually any week you choose. Conference Objectives are: * Recommend preventive lifestyle behaviors and protective pharmacothe­rapy. * Assess the appropriate­ness of th

American Educational Institute (AEI) Medical-Dental-Legal Update is organized by American Educational Institute (AEI) and will be held during Oct 02, 2017 - Sep 28, 2018 at Dickenson Square, Maui, Hawaii, United States of America. The target audience for this medical event is Dentists. This CME Conference has been approved for a maximum of 20 AMA PRA Category 1 Credits. Conference Description : You practice in a dynamic and challenging environment. While keeping clinically current is imperative, it isn't enough. You must also acquire the skills necessary to navigate a professional liability minefield, manage a more effective and efficient practice, and navigate a maze of healthcare laws and regulations. The 2017-18 Medical-Dental-Legal Update Update is designed to assist you in that endeavor. The course, offered weekly in 32 enviable destinations, is a unique, 20-hour survey of the intersection of medicine and law as well as selected clinical topics. Produced in state-of-the-art production studios with broadcast-grade, HD digital technology. This Conference offers vital instruction from national experts in the fields of law, medicine, dentistry, asset protection, revenue cycle management and practice management. And their presentations include discussions ranging from domestic violence, payment receipt optimization, medical malpractice, fraud and abuse, and optimizing retirement and benefit plan structures, to the oral-systemic connection, medical errors, Hepatitis B & C, neurology and cardiovascular fitness. Conference Objectives are: * Recommend preventive lifestyle behaviors and protective pharmacothe­rapy. * Assess the appropriate­ness of the direct patient care model for your practice * Utilize a variety of clinically relevant but relatively unknown treatments. * Better recognize and respond to victims of child violence. * Better understand and deal with medical malpractice litigation. * More effectively reduce practice risk and protect assets exposed t

Mayo Clinic Hospital Medicine: Managing Complex Patients is organized by Mayo Clinic and would be held during Nov 08 - 11, 2017 at Loews Ventana Canyon Resort, Tucson, Arizona, United States Of America. The target audience for this medical event for inpatient care providers including physicians, nurse practitioners and physician assistants. Hospitalists are defined as those who spend most of their professional practice caring for hospitalized patients. This CME Conference has been approved with a maximum of 25.25 AMA PRA Category 1 Credits. Hospital Medicine is the fastest growing medical specialty and requires a diverse skill set. Hospital-based health care providers must be able to diagnose and manage a wide variety of clinical conditions, coordinate transitions of care, provide perioperative management to surgical patients and contribute to quality improvement and hospital administration. This program is specifically designed to ensure that participants augment their skill set to meet these many challenges in an effort to enhance the delivery of health care and provide better patient outcomes. Using an interactive, case-based format, key highlights from most major areas of hospital medicine will be presented. Conference Objectives are : * Classify a patient presenting with MI according to the most recent guidelines. * Select the appropriate indications for troponin testing. * Manage a patient with subsegmental pulmonary embolism. * Define sepsis according to the most recent clinical guidelines. * Select the appropriate antibiotics for a hospitalized patient with health-care associated pneumonia. * List strategies to improve the mobility of elderly patients in the hospital. * Manage a patient admitted to the hospital with diabetic ketoacidosis. * Recognize common sources of cognitive bias and heuristics to minimize their impact on patient care. * Order the appropriate tests for a hospitalized patient with a newly-diagnosed pleural effusion. * List novel the

Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism. Melanie J. Davies, M.D., from the University Hospitals of Leicester NHS Trust in the United Kingdom, and colleagues conducted post hoc analysis using data from 5,908 participants in five randomized, double-blind, placebo-controlled clinical trials of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management, in order to assess cardiovascular risk. The researchers found that with liraglutide (3.0 mg), eight participants had positively adjudicated cardiovascular events (1.54 events/1,000 person-years), compared to 10 participants in the comparators group (3.65 events/1000 person-years). Compared to the non-liraglutide group, the hazard ratio for 3.0 mg liraglutide treatment was 0.42 (95 percent confidence interval, 0.17 to 1.08).

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C. Teng-Yu Lee, M.D., Ph.D., from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up. The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years (2.86 percent versus 5.59 percent). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.